Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

Tirzepatide, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic ... with mean fasting insulin percent reductions of 27.76% (P =.003; 10 mg dose) and 37.0% (P ...

Participants who tolerated 10 mg but did not tolerate 15 mg continued on 10 ... and GLP-1 (glucagon-like peptide-1) obesity medication. Tirzepatide tackles an underlying cause of excess weight. It ...

The N-terminal pro–B-type natriuretic peptide (NT-proBNP ... as compared with placebo — empagliflozin at a dose of 10 mg daily in the EMPEROR-Preserved trial (hazard ratio, 0.79; 95% CI ...

Mounjaro contains the active ingredient tirzepatide. It’s a type of drug called a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Department of Chemical and Materials Engineering, University of Kentucky, Lexington, Kentucky 40506, United States Department of Chemistry and Biochemistry, Butler University, Indianapolis, Indiana ...

Tirzepatide (Mounjaro, Eli Lilly) is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist for subcutaneous injection with a ...

Among these, several peptides were proposed for cosmeceutical applications, thanks to their specific interaction with biological targets. In this mini-review, we report some of the most investigated ...